Other languages Molecular Templates, Inc.

Equities

MTEM

US6085502085

Delayed Nasdaq Other stock markets 03:13:15 2024-05-15 pm EDT			5-day change	1st Jan Change
1.48 ^USD	-0.67%		-7.50%	-60.32%

Apr. 12	Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	CI
Apr. 09	Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	Apr. 12
Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	Apr. 09
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29
Molecular Templates, Inc. Provides Interim Update	Mar. 04
Molecular Templates, Inc. Announces Board Changes	Jan. 17
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	Nov. 02
Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023	23-09-28
Molecular Templates' Board Approves 1-for-15 Reverse Stock Split	23-08-11
Molecular Templates, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Molecular Templates, Inc. Announces Executive Changes	23-08-02
Molecular Templates Signs Deal for Up to $40 Million Private Placement	23-07-13
Molecular Templates Says US FDA Removed Partial Clinical Hold on Patient Enrollment for Phase 1 Multiple Myeloma Study	23-06-01
Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma	23-06-01
Molecular Templates, Inc. to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology Annual Meeting	23-05-26
Molecular Templates, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Molecular Templates Says FDA Placed Partial Clinical Hold on Phase 1 Study of MT-0169 Due to Cardiac Adverse Events	23-04-10
Molecular Templates, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
Sector Update: Health Care Stocks Outperform Most Other Sectors	23-03-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Molecular Templates, Inc.

Equities

MTEM

US6085502085

Other languages

Filters